Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry

EuPA Open Proteomics

Volumn 11, Issue , 2016, Pages 23-27

  Pacholarz, Kamila J ^a,b   Barran, Perdita E ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antibody Drug Conjugate (ADC); Drug to antibody ratio (DAR); Monoclonal antibodies (mAbs); Native mass spectrometry

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BUFFER; CYSTEINE; MONOCLONAL ANTIBODY; TRIETHYLAMMONIUM ACETATE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL PROCEDURES; CHEMICAL STRUCTURE; CONJUGATION; DEGYLCOSYLATION; DESOLVATION; DRUG DETERMINATION; ELECTRIC POTENTIAL; ELECTROSPRAY MASS SPECTROMETRY; FEASIBILITY STUDY; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 84961768931     PISSN: None     EISSN: 22129685     Source Type: Journal    
DOI: 10.1016/j.euprot.2016.02.004     Document Type: Article

References (40)

1. Chari R.V.J., Miller M.L., Widdison W.C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. 2014, 53(15):3796-3827.
2. Beck A. Review of antibody-drug conjugates, methods in molecular biology series. mAbs 2014, 6(1):30-33.
3. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Ann. Rev. Med. 2013, 64:15-29.
4. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23(9):1137-1146.
5. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30(7):631-637.
6. Leal M., Sapra P., Hurvitz S.A., Senter P., Wahl A., Schutten M., Shah D.K., Haddish-Berhane N., Kabbarah O. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann. N. Y. Acad. 2014, 1321(August):41-54.
7. Deonarain M.P., Yahioglu G., Stamati I., Marklew J. Emerging formats for next-generation antibody drug conjugates. Exp. Opin. Drug Discov. 2015, 10(5):463-481.
8. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., Shochat D., Mountain A., Flowers D.A., Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002, 13(1):47-58.
9. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., Lu Y., Meng Y.G., Ng C., Yang J., Lee C.C., Duenas E., Gorrell J., Katta V., Kim A., McDorman K., Flagella K., Venook R., Ross S., Spencer S.D., Wong W.L., Lowman H.B., Vandlen R., Sliwkowski M.X., Scheller R.H., Polakis P., Mallet W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26(8):925-932.
10. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom I., Hellstrom K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261(5118):212-215.
11. Francisco J.A., Cerveny C.G., Meyer D.L., Mixan B.J., Klussman K., Chace D.F., Rejniak S.X., Gordon K.A., DeBlanc R., Toki B.E., Law C.L., Doronina S.O., Siegall C.B., Senter P.D., Wahl A.F. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102(4):1458-1465.
12. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., Meyer D.L., Francisco J.A. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10(20):7063-7070.
13. Teicher B.A., Chari R.V.J. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 2011, 17(20):6389-6397.
14. Beck A., Wagner-Rousset E., Ayoub D., Van Dorsselaer A., Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Analytical Chemistry 2013, 85(2):715-736.
15. Thompson N.J., Rosati S., Heck A.J.R. Performing native mass spectrometry analysis on therapeutic antibodies. Methods 2014, 65(1):11-17.
16. Beck A., Terral G., Debaene F., Wagner-Rousset E., Marcoux J., Janin-Bussat M.-C., Colas O., Van Dorsselaer A., Cianférani S. Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibodydrug conjugates. Expert review of proteomics 2015, 13(2):157-183.
17. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011, 3(2):161-172.
18. Chen J., Yin S., Wu Y., Ouyang J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal. Chem. 2013, 85(3):1699-1704.
19. Bioanalysis Zone Antibody- Drug Conjugate Survey Infographic (accessed 02.07.15). http://www.bioanalysis-zone.com/2015/05/26/antibody-drug-conjugate-survey-infographic/.
20. Lazar A.C., Wang L.T., Blattler W.A., Amphlett G., Lambert J.M., Zhang W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19(13):1806-1814.
21. Xu K., Liu L., Saad O.M., Baudys J., Williams L., Leipold D., Shen B., Raab H., Junutula J.R., Kim A., Kaur S. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal. Biochem. 2011, 412(1):56-66.
22. Valliere-Douglass J.F., McFee W.A., Salas-Solano O. Native Intact mass determination of antibodies conjugated with monomethyl auristatin E and F at interchain cysteine residues. Anal. Chem. 2012, 84(6):2843-2849.
23. Hengel S.M., Sanderson R., Valliere-Douglass J., Nicholas N., Leiske C., Alley S.C. Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal. Chem. 2014, 86(7):3420-3425.
24. Debaene F., Boeuf A., Wagner-Rousset E., Colas O., Ayoub D., Corvaïa N., Van Dorsselaer A., Beck A., Cianférani S. Innovative native MS methodologies for Antibody Drug Conjugate Characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal. Chem. 2014, 86(21):10674-10683.
25. Valliere-Douglass J.F., Hengel S.M., Pan L.Y. Approaches to interchain cysteine-linked ADC characterization by mass spectrometry. Mol. Pharm. 2015, 12(6):1774-1783.
26. Dyachenko A., Wang G., Belov M., Makarov A., de Jong R.N., van den Bremer E.T.J., Parren P.W.H.I., Heck A.J.R. Tandem native mass-spectrometry on antibody-drug conjugates and submillion Da antibody-antigen protein assemblies on an Orbitrap EMR equipped with a high-mass quadrupole mass selector. Anal. Chem. 2015, 87(12):6095-6102.
27. Marcoux J., Champion T., Colas O., Wagner-Rousset E., Corvaia N., Van Dorsselaer A., Beck A. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci. 2015, 24:1210-1223.
28. Pacholarz K. PhD Thesis-Investigation of Large Proteins and Multimeric Protein Complex Structures with Mass Spectrometry Techniques 2015, University of Edinburgh, Edinburgh, United Kingdom.
29. Pagel K., Hyung S.-J., Ruotolo B.T., Robinson C.V. Alternate dissociation pathways identified in charge-reduced protein complex ions. Anal. Chem. 2010, 82(12):5363-5372.
30. Zhou M., Dagan S., Wysocki V.H. Protein subunits released by surface collisions of noncovalent complexes: nativelike compact structures revealed by ion mobility mass spectrometry. Angew. Chem. Int. Ed. 2012, 51(18):4336-4339.
31. Mehmood S., Marcoux J., Hopper J.T.S., Allison T.M., Liko I., Borysik A.J., Robinson C.V. Charge reduction stabilizes intact membrane protein complexes for mass spectrometry. J. Am. Chem. Soc. 2014, 136(49):17010-17012.
32. Hall Z., Politis A., Bush M.F., Smith L.J., Robinson C.V. Charge-state dependent compaction and dissociation of protein complexes: insights from ion mobility and molecular dynamics. J. Am. Chem. Soc. 2012, 134(7):3429-3438.
33. Catalina M.I., van den Heuvel R.H.H., van Duijn E., Heck A.J.R. Decharging of globular proteins and protein complexes in electrospray. Chem. Eur. J. 2005, 11(3):960-968.
34. Lemaire D., Marie G., Serani L., Laprevote O. Stabilization of gas-phase noncovalent macromolecular complexes in electrospray mass spectrometry using aqueous triethylammonium bicarbonate buffer. Anal. Chem. 2001, 73(8):1699-1706.
35. Hogan C.J., Carroll J.A., Rohrs H.W., Biswas P., Gross M.L. Combined charged residue-field emission model of macromolecular electrospray ionization. Anal. Chem. 2009, 81(1):369-377.
36. Hogan C.J., Carroll J.A., Rohrs H.W., Biswas P., Gross M.L. Charge carrier field emission determines the number of charges on native state proteins in electrospray ionization. J. Am. Chem. Soc. 2008, 130(22):6926-6927.
37. Wanasundara S.N., Thachuk M. Free energy barrier estimation for the dissociation of charged protein complexes in the gas phase. J. Phys. Chem. A 2009, 113(16):3814-3821.
38. Rosati S., van den Bremer E.T.J., Schuurman J., Parren P.W.H.I., Kamerling J.P., Heck A.J.R. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs 2013, 5(6):917-924.
39. Sandoval W.N., Arellano F., Arnott D., Raab H., Vandlen R., Lill J.R. Rapid removal of N-linked oligosaccharides using microwave assisted enzyme catalyzed deglycosylation. Int. J. Mass Spectrom. 2007, 259(1-3):117-123.
40. Arnott D.P., Lill J., Sandoval W.N., Vandlen R.L. Microwave Assisted Deglycosylation of Proteins for Molecular Weight Determination by Mass Spectrometry 2012, Official Gazette of the United States Patent and Trademark Office Patents.